share_log

Virpax Pharmaceuticals | 8-K: Current report

SEC announcement ·  Mar 18 06:34
Summary by Moomoo AI
Virpax Pharmaceuticals, Inc. has announced that it has regained compliance with Nasdaq's Listing Rule 5550(a)(2) after maintaining a closing bid price of $1.00 per share or greater for 10 consecutive business days from March 1 to March 14, 2024. The company received a Notification Letter from Nasdaq on March 15, 2024, confirming the regained compliance and closing the matter. Additionally, on March 14, 2024, the United States Bankruptcy Court for the Southern District of Texas approved a settlement agreement between Virpax Pharmaceuticals, Sorrento Therapeutics, Inc., and Scilex Pharmaceuticals Inc. The details of the settlement are outlined in the Settlement Agreement and Mutual Release filed with the SEC.
Virpax Pharmaceuticals, Inc. has announced that it has regained compliance with Nasdaq's Listing Rule 5550(a)(2) after maintaining a closing bid price of $1.00 per share or greater for 10 consecutive business days from March 1 to March 14, 2024. The company received a Notification Letter from Nasdaq on March 15, 2024, confirming the regained compliance and closing the matter. Additionally, on March 14, 2024, the United States Bankruptcy Court for the Southern District of Texas approved a settlement agreement between Virpax Pharmaceuticals, Sorrento Therapeutics, Inc., and Scilex Pharmaceuticals Inc. The details of the settlement are outlined in the Settlement Agreement and Mutual Release filed with the SEC.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more